Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative...

Area of Science:

• Cardiovascular Biology
• Hematology
• Molecular Medicine

Background:

• Patients with JAK2V617F-positive myeloproliferative neoplasms (MPNs) exhibit a heightened risk of cardiovascular diseases.
• The JAK2V617F mutation is found in endothelial cells of MPN patients, suggesting a role in cardiovascular complications.

Purpose of the Study:

• To investigate the molecular mechanisms underlying cardiovascular complications in MPNs.
• To determine the impact of endothelial JAK2V617F mutation on cardiovascular disease development.

Main Methods:

• Utilized transgenic murine models and patient-derived induced pluripotent stem cell lines.
• Examined the role of endothelial JAK2V617F mutation in cardiovascular disease.

Main Results:

• Endothelial JAK2V617F mutation promotes cardiovascular disease under stress, linked to endothelial-to-mesenchymal transition and dysfunction.
• Inhibition of the endothelial thrombopoietin receptor MPL suppressed mutant endothelial cell-induced cardiovascular dysfunction.
• Endothelial MPL is not critical for normal blood cell counts or cardiac function.

Conclusions:

• JAK2V617F mutant endothelial cells are key drivers of cardiovascular disease in JAK2V617F-positive MPNs.
• Targeting the endothelial MPL receptor presents a promising strategy for managing cardiovascular complications in MPN patients.